StemCell Therapy

ORLANDO, Fla., Oct. 18, 2019 /PRNewswire-PRWeb/ -- The Laser Institute (LIA)'s 38th International Congress on Applications of Lasers & Electro-Optics (ICALEO) was recently held in Orlando, Florida and featured the conference's many firsts. A meeting of laser industry experts and decision-makers from around the world, the event hosted dialogue with a deeper industry foci, more expansive technical sessions, and a new Business Conference that addressed laser end-users while highlighting solutions from the manufacturing community.

A collection of Live User Solutions Forums, Market Drivers Symposia, and Live User Solutions Round Tables discussions, the Business Conference acted as a complement to ICALEO's traditional Technical Conference. Regarded as a concentrated effort of participants from the Aerospace, Biomedical, Microelectronics, and Automotive industries, ICALEO's Business sessions allowed laser manufacturers, integrators, and end-users to engage in the discussion on the unique challenges and revolutionary applications in the industry.

To further emphasize the attendee-friendly approach of this year's ICALEO format, the Business Conference also presented a four-day tradeshow that connected all members of the laser marketplace. An accomplishment at dedicating whole days to each of its selected industries, the tradeshow hosted over 40 international exhibitors from the likes of IPG Photonics, II-VI, and more.

Spanning the duration of the conference to maximize the attendee's opportunity to network with these leading brands, the assembly of exhibitors also included Han's Laser Smart Equipment Group (ICALEO's Diamond Sponsor), Coherent Inc. (ICALEO's Platinum Sponsor), as well as TRUMPF Inc., Kentek, and Edgewave (ICALEO's Gold Sponsors).

Meanwhile, the ICALEO Technical Conference enhanced its focus on the innovative and novel uses of lasers and photonics via its subdivided tracks. These are comprised of the Laser Additive Manufacturing, Laser Materials Macroprocessing, Laser Materials Microprocessing, Laser Nanomanufacturing, and Battery Systems and Energy Conversion tracks.

An approach that allowed the conference speakers to deliberate on how laser applications can push the envelope of modern technology while advancing key industries in their accuracy, efficiency, and speed, the Technical Conference's new format also gave engineers and materials processing experts the chance to discover new processing techniques, acquire new skills, and collaborate to ensure their organization stays up-to-date and on the leading edge of productivity.

These innovations and advancements were envisioned in the opening addresses of the plenary speakers from all four industries. Peter Boeijink of XYREC opened the aerospace-focused conference with his speech on "The Largest, Highest-Power, Mobile, Industrial, Laser Materials Processing Robot in the World" while Dr. Christoph Leyens from Fraunhofer IWS discussed the "Innovative Aerospace and Space Structures Made by Additive Manufacturing."

Similarly, the esteemed Professor William Steen presented his speech "The Coming of the Age of Optical Engineering" during the biomedical conference, alongside Fraunhofer Institute of Laser Technology (ILT)'s Dr. Nadine Nottrodt who spoke on "Laser in Biofabrication How Laser Technology Can Help to Build Artificial Tissue." They were joined by Dr. Chris Bashur of the Florida Institute of Technology who elaborated on the "Photonic Needs in Regenerative Medicine."

Participants from the microelectronics industry mulled over the words of Dr. Kumar Patel of Pranalytica Inc. during his plenary speech on "Recapturing the Excitement of High Power Infrared Lasers," while Dr. Markus Arendt of SUSS MicroTec Photonic Systems spoke on the "Excimer Laser Ablation for High-Density Routing in Advanced Packaging."

During the automotive-focused conference, Ethan Sprague from the University of Michigan presented his thoughts on "Laser Aided Manufacturing: Atom to Automobile" before Dr. Ted Reutzel of Pennsylvania State University described the "Progress Towards Sensing and Mitigating Flaw Formation in Powder Bed Fusion Additive Manufacturing." Their presentations joined the observations on "Bottoms Up Digital Design: The Quiet Revolution of the Additive Manufacturing Age" by Dr. Jason Carroll of Eaton, a power-management company that provides energy-efficient solutions to managing electrical, hydraulic, and mechanical power.

To view the highlighted content from ICALEO 2019, including recorded interviews, panels, and speeches, follow LIA's social media profiles on Facebook, Twitter, and LinkedIn. The 39th ICALEO will be held at the McCormick Place Convention Center in Chicago, Illinois USA from Oct 19, 2020Oct 22, 2020. Call for papers and Tradeshow booth bookings will be made available soon, and interested parties may contact icaleo@lia.org for further information.

SOURCE The Laser Institute

Here is the original post:
Future of Laser Innovations Reflected at Revamped ICALEO Conference - Benzinga

Post-mortem scans of injured brains are causing researchers to question the hypothesis that blunt force trauma from traumatic brain injuries (TBI) causes nerve damage.

The scans, conducted by a team including researchers at the New York-based Cold Spring Harbor Laboratory (CSHL), have shown greater signs of blood vessel damage than nerve damage, and could influence how drugs are developed and treatments are implemented for TBI.

CSHL professor Partha Mitra said: Nerve damage following traumatic brain injuries has been a majority point of view, and therapy as well as drug development has been targeted towards that.

The idea is that if the mechanism is actually different, therapeutic intervention may also be different.

The CSHL team performed close analysis on post-mortem brain tissue using a high-throughput neurohistological pipeline, an assemblage of techniques for labelling and visualising brain slices, which Mitra had developed to study mouse brains.

Scanning the brains in this way provides much clearer images than magnetic resonance imaging (MRI) alone. While MRI can show clinicians that brain damage has occurred, the resolution is limited and it can be hard to discern whether nerve or vascular injury has occurred.

Correlating neurohistological pipeline scanning with MRI scans allowed the team to see the vascular injuries more clearly.

The researchers focused on areas surrounding lesions where trauma had left a physical impact on the brain, which appeared on the MRI scans as black spots.

They then used an iron stain to test for the presence of blood and a myelin stain to test of the presence of nerve fibre fragments in the brain samples. While a significant amount of iron-marked stains appeared in the brain samples in these areas, indicating traumatic microbleeds in the tissue, the researchers did not find any significant nerve damage from the myelin stains.

The researchers concluded that traumatic vascular injury is distinct from nerve damage and could thus be a target for new therapies. They also found that these traumatic microbleeds could often predict future health problems and disabilities for people with TBI, although they could not determine their relationship with acute problems.

The study has been published in the neurology journal Brain.

The team now hopes to conduct research into the underlying causes and effects of TBI for better diagnosis, prognosis, therapeutic targets and patient outcomes.

CSHL worked with colleagues at the National Institutes of Health, National Institute of Neurological Disease and Stroke, University of Maryland, Center for Neuroscience and Regenerative Medicine, and Uniformed Services University of the Health Sciences, which had been studying the brains of deceased patients using MRI.

Enter your details here to receive your free whitepaper.

Close survey

Close

Read the original:
Nerve damage not the root cause for symptoms of traumatic brain injury - Medical Device Network

In 2006, Shinya Yamanaka shook stem cell research with his discovery that mature cells can be converted into stem cells, relieving a longstanding political-ethical blockage and throwing open medical research on everything from curbing eye degeneration to organ printing.

But that process still has pitfalls, including in risk and scalability, and some researchers are exploring another way first hinted at years ago: new technology to convert mature cells directly into other mature cells without the complex and time-consuming process of first making them into stem cells.

One of those companies, Mogrify, just raised $16 million in Series A financing to bring its overall funding to over $20 million since its February launch. Led by CEO Darrin Disley, the funding will help expand their new base in Cambridge to a 60-strong staff and push forward their direct-conversion approach to cell therapy through research and licensing. Investors include Parkwalk Advisors and Ahren Innovation Capital.

They list potential applications as treatments for musculoskeletal and auto-immune disorders, cancer immunotherapy, and therapies for ocular and respiratory diseases. For example, you could use it regenerate cartilage in arthritis patients.

If you could take a cell from one part of the body and turn it into any other cell at any other stage of development for another part of the body, you effectively have the Holy Grail of regenerative medicine, Disley told Labiotech.eu in April.

Mogrifys advantage over the Yamanaka method called induced pluripotent stem cells (iPS), is that in theory it can be more scalable and avoid the problems associated with iPS. These include instabilities arising from the induced immature state and an increased risk of cancer if any pluripotent cells remain in the body.

The concept behind Mogrify actually predates, by nearly 19 years, Yamanakas discovery, which fast won him the 2012 Nobel Prize in Medicine. A 2017 Nature study on transdifferentiation, as the process is called, of fibroblasts into cardiac tissue traced the idea to a 1987 findingthat a master gene regulator could convert mice fibroblasts into skeletal muscle.

The problem though, according to Mogrify, is that most current efforts rely on an exhausting guess-and-check process. With hundreds of cell types and an even greater number of transcription factors the program that recodes the cell finding the right factor for the right cell can be like a custodian with a jangling, unmarked key ring trying to get into a building with thousands of locks.

Mogrifys key tech is a computer model they say can predict the right combination. The scientists behind the platform published a 2016 study in Nature applying the model to 173 human cell types and 134 tissues.

Before Mogrify, Disley led the Cambridge-based gene-editing company Horizon Discovery.

Originally posted here:
Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine - Endpoints News

Delegates from the American Academy of Stem Cell Physicians recently traveled to the Bahamas to meet with the Governor General Sir Cornelius Alvin Smith to discus medical industry safety standards.

While in the Bahamas the delegates attended a 3 day regenerative health summit for educators, experts, professionals and learners where in doctors from all over the world arrived to discuss the future of regenerative medicine and stem cell therapy.

Dr. Krutchkoff announced the launch of the AASCPs Research Consortium dedicated to supporting research to validate therapies and promote compliance within the industry. During the HEALinc Summit Dr. Farschian and Dr. Krutchoff, the American Academy of Stem Cell Physicians delegates, held a workshop to teach physicians about a pathway to compliance when utilizing cell therapies in their practices.

The AASCP was created to advance research and the development of therapeutics in regenerative medicine, and aims to serve as an educational resource for scientists, physicians, and the public in diseases that can be caused by physiological dysfunction that are ameliorable to medical treatment.

The HEALinc Summit was organized by Dr. Desiree Cox, CEO of the HEALinc Future of Health Innovation Summit and The HEALinc Innovation Incubator which is a movement based organization with a mandate to champion a future health paradigm where medical therapy is driven by personal health and regenerative medicine by incorporating ongoing, real world capture, predictive analytics, and education.

Dr. Cox currently chairs the National Stem Cell Ethics Committee for the Bahamas, and has been leading health innovation and the development of the stem cell and regenerative industry since 2015 in the Bahamas which is a fast track test bed for real world studies in stem cell, regenerative medicine, and medical devices among others.

During the HEALinc Summit leading international experts spoke on hot topics in stem cell therapy, longevity and vitality, regeneration, resilience and adaptability, precision health, epigenetic and nutrition, personal wellness and optimal health, regenerative ventures/investment and much more.

"Within the Bahamas, health innovations in cellular and gene therapies, regenerative medicine, precision medicine and digital health can be tested ethically and safely in a regulated environment, so that the data obtained from the research can be used in later applications for FDA or EMA approval, says Dr. Cox.

Dr. AJ Farshchian, spokesperson for AASCP said, "It was a great honor meeting the Governor General in the Bahamas. We discussed safety standards currently practiced in the industry and how to improve the industry moving forward."

Dr. Adam Shwani, a member of the board for the American Academy of Stem Cell Physicians, added, "It is so important to bring industry partners together from all over the world to develop a standard that promotes patient safety and encourages growth in the field of regenerative medicine.

Go here to see the original:
AASCP Delegates Meet With The Governor General Of The Bahamas - Anti Aging News

Enso Discoveries is proud to partner with the Kansas Department of Agriculture for the fourth year to bring the veterinary and agricultural industries in the midwest the Kansas Veterinary Regenerative Symposium as part of the Kansas Veterinary Medicine Association Annual Meeting.

MANHATTAN, Kan., Oct. 17, 2019 /PRNewswire-PRWeb/ -- Enso Discoveries, the perennial sponsor of the Kansas Veterinary Regenerative Symposium (KVRS), proudly announces the 4th annual session hosted by the Kansas Department of Agriculture (KDA) on the second day of the Fall Kansas Veterinary Convention & Kansas Veterinary Medicine Association (KVMA) Annual Meeting happening in Manhattan, Kansas from November 8-10, 2019.

The Fall Kansas Veterinary Convention promises over 40 hours of quality education in small and large animal medicine, practice management and veterinary technicians. Speaking sessions, wet labs and workshops offer practical information, flexible schedule, networking and more over the three-day event.

"The mission of the KVRS has always been to concisely educate the practicing veterinarian about regenerative medicine in such a way that they can immediately implement into their practice. Once a treatment option available only to a limited few, it is now available for most every patient, so being informed has never been more important," said Corey Orava, DVM, CSO of Enso Discoveries and Chair of KVRS.

This year KVRS will have four speakers from both academia and private practice. The general theme of the Symposium will be regenerative therapies in veterinary medicine with topics including Platelet Rich Plasma and Platelet Rich Fibrin in both large and small animal practice:

Date: November 9, 2019 Time: 1:30 PM Location: Hilton Garden Inn & Conference Center Address: 410 S. 3rd Street, Manhattan, KS 66502

"Using the body to heal itself is the perfect marriage of natural and advanced technology. It is truly a marvel to witness the progress of my patients. I can't say enough about Enso Discoveries and the easy-to-use kits we now use to offer PRP as a service to our clients." - Kendell Michel, DVM, CVCP, Family Animal Care of Salina, Kansas

### Our mission at Enso Discoveries is to greatly enhance the lives of animals through the development of cutting-edge, novel technology. We believe all things are possible. We offer a wide range of innovative services, university-backed science, and affordable medical products with an emphasis on regenerative medicine.

We continually perform and fund veterinary research with the help of our academic and industrial research partners. While maintaining the highest level of integrity, we continue to succeed because we support our products and services with scientific proof, superior sales and marketing ability, and a worldwide network of industry experienced contacts.

Visit link:
Enso Discoveries and Kansas Department of Agriculture will Host the 4th Annual Kansas Veterinary Regenerative Symposium on Saturday, November 9, 2019...

Nassau, The Bahamas The best and brightest global recently gathered in The Bahamas to discuss ways of making stem cell and regenerative health technologies available, accessible and affordable to everyone, everywhere.

Dr. Desiree Cox, Rhodes Scholar and Founder and CEO of HEALinc reflects, This event promotes research and innovation in medical technologies with the potential to help people stay healthy through their lifespan. Our presenters and sponsors delivered an immersive experience that bridged the gaps between modern regenerative medicine technologies and ancient healing arts of creativity, music, movement and breathwork.

The second annual HEALinc Future Health and Innovation Summit was hosted at the Grand Hyatt, Baha Mar Convention Center from October 2 4, 2019 with an audience of more than 200-participants. A slate of more than 50 presenters delivered thought-provoking presentations and the celebrity keynote speech was given by Dr. Joe Dispenza,an international lecturer, researcher and author who has been invited to speak in more than 33 countries on six continents. Dr. Dispenza challenged the audience to rewire the brains and recondition their bodies to make lasting life changes.

Dr. Steven Greco, Chief Scientific Officer of the Houston Healthspan Innovation Group said, Regenerative medicine and immune restoration treatments provide safe, accessible options for patients. Houston Healthspan was pleased to share some of the exciting pilot data related to orthopedic and neurological treatments delivered at Okyanos. Through our participation and the sponsorship of the Bosarge Family Foundation, we were able to collaborate on this Summit because of our shared commitment to HEALinc., and to The Bahamas.

Dr. Joshua Hare, Professor of Medicine at University of Miami and Co-founder and Chief Scientific Officer of Longeveron, presented important scientific data from Longeverons multiple FDA authorized stem cell trials in the US as well as the 60+ patients treated in The Bahamas in Longeverons approved open Registry for aging and musculoskeletal related disorders.Dr. Todd McAllister, CEO of Fountain Therapeutics scheduled to begin operations in Bimini was a keynote speaker at the Summit along with Dr. Robert Hariri, Founder and President of Celularity, and one of the angel investors of Fountain Therapeutics along with Peter Diamandis and Tony Robbins. Dr. Hariri says, This Summit is an ideal environment to engage in conversations that affirm our commitment to harnessing the powerful biology of the placenta to treat cancer, immunological and degenerative diseases and we commend Dr. Cox for her leadership in this regard.

Dr. Cox says, As we grow, we anticipate hosting events in the United States that provide a space for more individuals to showcase products and services that will allow more persons to live longer, healthier and happier lives because of the integration of modern and ancient regenerative health technologies.

Continued here:
Second annual Regenerative Medicine summit proves big win for The Bahamas - EyeWitness News

TOKYO--(BUSINESS WIRE)--Utilizing the capability of ones own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved way for a new chapter in oncology, inspired many young scientists and clinicians in the NCRM NICHE 2019 held in Tokyo, Japan, as his acceptance speech in the Edogawa NICHE Prize ceremony was videocast.

NCRM NICHE, an active knowledge gaining academic event since 2006 in which young scholars from all over the world compete for the Fujio Cup Quiz (FCQ) in regenerative medicine is evolving to be an open innovation platform according to Dr. Shojiro Katoh, Chairperson of Edogawa Evolutionary Lab of Science (www.eels.tokyo), a co-host. He added that the FCQ motivated his team research on 16 different themes in Regenerative Medicine in various clinical specialties, among which two have completed clinical pilot studies with successful outcome viz., corneal endothelial regeneration and urethral stricture repair.

The XIV edition of FCQ contest that witnessed teams from Malaysia, Indonesia and India in the finals, was won by Reshma Romanas and Aayurshi Agrahari of Kasturba Medical College, India. Alumni of the FCQ are now eligible to nominate the awardees for Edogawa NICHE Prize which was established in 2018 to honour scientists or clinicians who develop novel solutions in healthcare, based on inter-disciplinary interactions. Dr. Steven A. Rosenberg, Chief of surgery, National Cancer Institute, NIH, USA is the recipient of the award in 2019. The award portrays such accomplished role models to the FCQ Elites according to the organizers who have instituted Joyce & James Till Travel Grant with a generous grant by Prof James Till, that supports travel of yesteryears FCQ Elites, who are now accomplished researchers in their own rights to meet and inspire the FCQ Elites of today, thus bringing together science and generations across nations.

NCRM NICHE is supported by a consortium with EELS as knowledge partners and JBM Inc., as industry partners based in Tokyo which has set up a hybrid cell culture cum biomaterials lab for taking forward the cell therapy and tissue engineering innovations to bed side, with future plans to propagate them globally through networking with like-minded academic and industry partners.

Originally posted here:
Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by...

MANCHESTER Now that the world has the Impossible Whopper, will the impossible liver be far behind?

Such possibilities are being broached this week as inventor Dean Kamen, founder of the Advanced Regenerative Manufacturing Institute, hosts the fourth semi-annual summit since launching ARMI in July 2017.

The three-day conference started Tuesday with a members-only day for BioFab USA and ARMI. It included a dinner at Kamens Bedford home.

Two public days of speeches and workshops are scheduled through Thursday. A total of 150 have signed up for the event.

Guests listen to a speaker at the Meeting in the Millyard at ARMI in Manchester on Wednesday, Oct. 16, 2019.

The keynote speaker on Wednesday was Jason Kelly, co-founder and chief-executive of Ginkgo Bioworks, a synthetic biology company that programs cells for customers in the chemical, pharmaceutical, food and energy industries.

We program cells because they run on digital code in the form of DNA, Kelly told a crowd of scientists, entrepreneurs and regulators.

Much of ARMIs work has focused on the use of stem cells to generate replacements for human tissue, bones and organs. For example, one of ARMIs biggest accomplishments to date has been the Tissue Foundry; its first production was bone-ligament tissue grown together from bone-marrow stem cells.

But Kamen, who prides himself on introducing new technologies to a field, had Kelly speak about a different kind of cells synthetic cells.

Ginkgo Bioworks has partnered with Bayer to develop self-fertilizing crops, with Roche to develop antibiotics, and with Motif to produce animal-free protein ingredients. Kelly said synthetic cell production played a role in the Impossible Whopper, the plant-based patty that Burger King claims tastes like beef.

(According to the website of Impossible Food, the company that makes the patty, the company extracts DNA from soy plants and inserts it into genetically engineered yeast, which ferments to produce heme, the molecule that gives meat its taste.)

Ginkgo has made CNBCs Disruptor 50 List in the last three years and recently raised more than $430 million in venture capital. In doing so, Ginkgo has achieved what Kamen wants for ARMI to move from theoretical design and laboratory work to mass production.

Theyve learned how to scale it, Kamen said in his introduction. Kamen said he expects ARMI-linked production to start relatively quickly.

(Finding) talent is not the problem. Capital is the problem, Kelly said about tech startups. Many venture capitalists arent experts in the science-heavy world of what he calls tough tech. So they are wary about investing in something they cant grasp.

He advised startups to seek government grants Ginkgo would not have succeeded without them hustle the non-specialist investor and find third-party validation from agencies such as the FDA or the Standards Coordinating Body, a voluntary organization that sets standards for the regenerative medicine industry.

Kelly said the time is now for tough tech. He noted the work of SpaceX and Tesla, and he said Silicon Valley is embracing biotech.

People have run out of things to invent that end up as a square on your phone, he said.

Go here to read the rest:
ARMI summit: With synthetic meat within grasp, why not synthetic liver? - The Union Leader

Alexis Nolfi went to her doctor one day to get treatment for her dry eyes.

Nolfi, a graduatebioengineeringstudent researcher in the University of PittsburghsSwanson School of Engineering, has been dealing this condition for several years now and the eye drop treatments she had been taking were only working temporarily, so she was using eye drops multiple times a day.

Its been pretty frustrating and borderline debilitating, said Nolfi. I had been using artificial tears every night and all through the day. I still use them all the time and havent been getting adequate relief, and I fight with my insurance company to cover prescription eye drop treatments.

However, this 2018 visit to her eye doctor,Vishal Jhanji, would be different.

While talking with each other in the doctors office, they realized the need for better treatment options for dry eye syndrome, which affects millions of Americans each year.

Dry eye is the most common reason patients come into our office, said Jhanji, a professor ofophthalmologyin PittsSchool of Medicine. She (Nolfi) had been using eye drops 10 to 15 times a day.

Nolfi then decided to experiment with contact lenses given to her by Jhanji to develop a new therapy tool and drug delivery system to target inflammation that can cause this irritating condition. What came out of it was the CyteSolutions Lens, a silicone-hydrogel-based contact lens coated with natural biopolymers organic molecular structures containing adrugthat targets inflammatory dry eye pathways not targeted by any other current treatments.

The coating is only activated and degraded whenever it makes contact with the surface of your eye, because there are enzymes in your eyes that work to degrade the polymers we use, said Nolfi. This allows the slow and safe release of drugs over a period of hours or even days as opposed to drops that almost immediately fall out of or drain away from your eyes.

While contact lens-based therapies have been previously developed by dipping lenses in drug solutions, the team is using biopolymers for slow and sustained drug delivery to target the inflammatory pathways in the eye.

There is a definite need for innovation and ways to deliver drugs to the surface of the eye, Jhanji said. Were not looking to simply replenish the eye; were trying to tackle the root cause of this problem.

Nolfi and Jhanji, along with Swanson School researchersMangesh KulkarniandBryan Brown, recently won one of three $100,000 grand prizes at the 2019 Pitt Innovation Challenge, hosted by Pitts Clinical and Translational Science Institute, to further advance their innovation.

Jhanji said dry eye syndrome has become more common in the 21stcentury, and with that has come more treatment options, ranging from over-the-counter eye drops to surgery depending on the patient.

The CyteSolutions Lens team wishes to eventually take their prototype to clinical trials and will ramp up studies thanks to the competitions funding. The researchers said anyone who uses contact lenses would be good candidates to try CyteSolutions Lens.

We dont expect this lens to feel any different from standard soft contact lenses, and theyre natural with no chemical crosslinking, said Jhanji.

PittsInnovation Institute, theMcGowan Institute for Regenerative Medicineand the UPMC Eye Centerassisted with research on the CyteSolutions Lens.

Continued here:
Researchers See Future of Dry Eye Treatment in Innovative Contact Lens - UPJ Athletics

The regenerative medicine market is predicted to develop at a CAGR of 25.4%, driven by the growing cell-based immunotherapy sector.

Cell therapies are the major driver behind the growth and will leap from being worth $13.2 bn in 2019 to $45.7bn in 2026 resulting in a compound annual growth rate (CAGR) of 23.8%, according to a Acumen Research and Consulting report.

In terms of causal reasons for the growth, the demand for such therapies is fuelled by a global ageing population and the rising incidence of cancer.

As a result, oncology has become a major therapeutic focus for companies with over a third of the current cell and gene therapy pipeline orientated toward finding a treatment for cancer.

Get Free Sample Copy@ https://www.acumenresearchandconsulting.com/request-sample/337

However, the specialist treatments often come with a higher price tag, compared to traditionally developed treatments, and as such, the highest growth will be seen in countries with growing health care sectors and those with populations that have the highest disposable incomes.

The niche within cell therapies that is seeing particularly high investment is chimeric antigen receptor (CAR)-T therapies, which has seen two treatment approvals in the US and Europe. In addition, there are number of other CAR-T therapies currently in clinical trials globally.

The development of the area has led to a number of acquisitions taking place in the sector, such as Gileads takeover of Kite, to gain access to its CAR-T treatment, and Novartis acquiring CellforCure to expand its manufacturing network for cell and gene therapies.

Despite the highest growth seen in the oncology sector, the overall largest market is for muscoskeletal disorders. This is due to the rise of orthopaedic diseases and injuries related to a rising geriatric population.

Geographically, the North American region accounts for the largest share of the regenerative medicine market.

Editor-in-Chief

20+ years of diverse and extensive experience in higher education including teaching, research, and university and community service in overseas universities and colleges.Associate Editor, and publications in international refereed journals and presented most of them in international conferences in the fields of Applied Multivariate Statistics, Mortality, Social Science, Economics.

Mail: globalqyresearch@gmail.com

Follow this link:
Regenerative Medicine Market Predicted to Develop at a 23.8% of CAGR - Story of Future

Companies that reject shareholder primacythat prioritize the needs of society, community, consumers, and employees above shareholder valueand those that fully understand the social and environmental impacts of their entire supply chain, irrespective of product or industry, will be the ones to thrive.

Companies that reject shareholder primacythat prioritize the needs of society, community, consumers, and employees above shareholder valueand those that fully understand the social and environmental impacts of their entire supply chain, irrespective of product or industry, will be the ones to thrive.

To define the characteristics of those companies: They will demonstrate emotional intelligence, flexibility, and the ability to adapt to complex, quickly-shifting conditions, work forces, and social movements. The companies that develop innovative products and services designed to protect people from climate impacts (sea-level rise, extreme heat, disaster) will prosper as well. Examples are companies that make cooling vests for outdoor workers, police officers, and firefighters; flood-response companies; design firms that build resilient structures capable of floating or adapting to rising waters; even private extraction companies like those being used by oil and gas entities to extract personnel from harmful situations like political conflicts, violence, or natural disasters.Further, companies with a majority of women on their boards and executive teams will outperform competitors and lead in their industry. In fact, I would venture that the numbers of men will flip to a women-led majority in most everything in the next 50 years.

Finally, given the increase in both the types of risk and the size of risk exposures such as hurricane, drought, extreme heat, and floods, property and casualty industry will finally transform. Along with reinsurance companies, they will offer individual policies that pay quickly based on a metric such as wind speed or sustained temperature.

More:
What will the world look like in 50 years? - Quartz

The biofabrication race is on. Scientists around the world are competing and the rise of biotechnological commercial players has diversified the field, moving fast to keep up with high expectations from scientists, healthcare providers and pharmaceutical companies eager to take the research to clinical therapy. But this is no easy transition, and even though bioprinting has moved the field forward, it is not as close to patients as everyone hopes it would be. One new company is now bringing a different message, one of possibility and hope that could pave the way for the future of healthcare.

Newly launched mimiX biotherapeutics is developing the next generation of biofabrication solutions to provide Point-of-Care tissue engineering for regenerative, personalized and precision medicine. Founded by Marc Thurner, who just this year left his previous creation regenHU and is now beginning a new chapter in his life, the startup will commercialize a new bioprocessing technology called Sound Induced Morphogenesis (SIM). Off to a new start, Thurnernow the CEO of mimiX biotherapeuticsspoke with 3DPrint.com about the scientific tool he expects could revolutionize regenerative medicine and diagnostics, and which he expects to launch commercially by next summer.

Could we accelerate the biofabrication revolution in the healthcare industry? wondered Thurner back in June.

This is a big question and one which he believes to have found the answer.

Just after I left regenHU, I began touring the countryside with my family. But I quickly went from a camping experience to a new tech venture. Tiziano Serra (the inventor of 3D-SIM technology) came to see me claiming he had an interesting technology in the field of biofabrication. After spending a week looking over some of the amazing scientific results and data he had developed throughout the last six years I decided this was an opportunity I couldnt miss, revealed Thurner. At the time, I realized that the technology most of the bioprinting companies have, which are based on conventional extrusion systems, are a great tool for scientific research but will probably never make the translation into the clinical environment, he revealed.

Marc Thurner

Instead, mimiX biotherapeutics technology has already demonstrated with scientific evidence that it offers tissue engineering strategies to overcome todays obstacles, for example, the creation of dense networks of cell suitable for micro vascularization.

According to Thurner, bioprinting using conventional dispensing systems is good for science but much too complicated for clinical use due to several critical hurdles including scalability, affordability, manufacturing, and because they entail complicated and labor-intensive processes.

He also claims that the current cell therapy available is costly and time-consuming since patients own biopsies are sent to labs where cells are isolated and amplified to create artificial tissue using 3D printing (or other more conventional methods) so that they can weeks later be transplanted back into the patient. It just takes too long.

It seems clear that we need to overcome this rudimentary process which is not stable and a logistical nightmare. Instead, mimiX biotherapeutics opens the door to manufacturing patient-specific tissues directly in the operating room (OR), enhancing patients autologous biological materials, for their own treatment. So, we see an opportunity to reduce the cost of the tissue engineering procedure. Moreover, we hope that in the future, most medical practitioners will be able to use the patients own biological material to process it directly in the OR without the need of any specific expertise in engineering or robotic tools required by typical bioprinters.

Delivering their technology to the clinical environment is the ultimate goal for the startup, which is headquartered in Neuchtel, Switzerland. Thurner hopes that one day every hospital will have a 3D-SIM system in the OR, to enhance the biomaterial that they obtain from the patient, and create tissue that is ready to be implanted within a few minutes.

Thurner went on to say that this could be possible within a timeframe of 10 years because we are simplifying the process and because the materials dont have to go out of the OR. This means that beyond patient care, we are also offering a solution to one of the biggest problems the healthcare industry has: extremely high costs.

Tiziano Serra

The 3D-SIM technology behind mimiX biotherapeutics is nearly a decade old. It was developed by Tiziano Serra, a Research Scientist at the AO Research Institute in Davos, Switzerland, with the objective of creating well-defined biological patterns that self-assemble into functional tissues using sound waves. A process Serra has poetically defined as orchestrating biology. The company states that SIM is a cell and biologics patterning process to create a 3D biological template in which cells induce morphogenesis through a self-assembly mechanism. SIM technology offers a highly efficient strategy creating dense and organized cell patterns.

The beauty behind SIM is that Serra began exploring its potential many years ago and already understands which type of patterns induce different types of tissue engineering strategies. Our current focus is on micro vascularization, which is the big bottleneck in regenerative medicine.

Our universe is immersed in waves, and mimiX biotherapeutics machines transmit them. A proprietary Labware is first placed on a type of speaker and depending on the sound emitted, the waves that are generated transmit energy to the labware and the cell-cultured media. The cells will then be patterned in different forms, such as circular, square, star shape or in agglomerates to trigger a self-assembly process. The company plans to deliver its novel instrument as a scientific tool next year for the research community, allowing them to explore the potential of what they could achieve when switching from conventional bioprinting to SIM. The small device fits any biosafety cabinet, and Thurner hopes that it will exponentially trigger the intellectual property behind the technology.

Marc Thurner

The company is driven by experienced healthcare, life science managers and scientists and benefits from cooperation with the AO Foundation, a nonprofit organization dedicated to improving the care of people with musculoskeletal injuries and their sequels through research, development, education and quality assurance.

Thurner has already begun setting up strategic partnerships to move forward with research and development, clinical trials, and luring strategic investors to join the venture. He is already preparing for a Series A round of financing to go to market with his prototype and start a clinical journey.

I am convinced we need to work with an open innovation mindset because the field of biofabrication is so versatile. To enable a revolution we need to bring together our expertise in hardware and software, along with cell therapy, clinical and healthcare knowledge. Even more so, our device will be an ideal lab instrument with the potential to be used in many fields, from biotechnology to drug discovery, concluded the expert.

Read more:
Marc Thurner Launches mimiX Biotherapeutics to Bioprint in the OR Using Sound - 3DPrint.com

SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Medtec China 2019, organized by Informa Markets, was successfully held at Shanghai World Expo Exhibition & Convention Center. It brought together 436 exhibitors from 25 countries and regions, including 150 first-time exhibitors; international exhibitors accounting for 56% of the turnout. The exhibition handled 28,057 visitors over three days, mainly professionals of R&D / Technology, Production / Manufacturing, Purchasing, Quality, Regulatory Affairs, and Senior Management from 41 countries and regions.

Industry leaders gather at a Medtec China that provides wide choice for procurement

Medtec China brings together and continues to attract leading medical device manufacturers from home and abroad, to exhibit a great many high-quality innovative technologies and products for the audience, thereby meeting the ever-increasing needs in the medical market.

Tekni - Plex, Suzhou Bank Valley, Baoji Xinuo, DuPont and other material suppliers exhibited Cellene thermoplastic elastomeric particles, medical absorbable biodegradable polymer materials, medical titanium, and the new packaging material Tyvek 40L; Delta Precision, Shanghai Y&L, Gowin Mold, and other enterprises exhibited high-precision and micro-machinery parts, holistic processing and manufacturing systems, and hot runner systems; JoyMed Technology and JCBIO are committed to providing a full range of commissioned product development, clinical, registration and OEM services for small and medium medical device enterprises and clinical institutions around the world. Medical automation device providers, such as Mikron, Team Technik and KAHLE Automation SRL, provide reliable assembly and testing lines for complex products, including POC diagnostic equipment, self-service pen injectors, dialysis filters, inhalers, infusion apparatus, insulin pens, pre-filled syringe, safe indwelling needles, and infusion tubes.

Conferences and forums following the industry focus, full house onsite

Chinese Regulatory Updates and Compliance, the 7th IIMD China Summit, Risk Management of Medical Product Life Cycle, MDR's MDSAP, and MDSAP&QSIT inspection all took place during Medtec to heightened interest. Lin Feng (Director, Medical Device Registry at Shanghai Food & Drug Administration), Feng Xiaoming (Deputy Director, National Institutes for Food and Drug Control (NIFDC) Biomaterials and Tissue Engineering Office), Xi Tingfei (Director of the Medical Device Inspection Center of the China National Institutes for Food and Drug Control), Shao Linyun (Deputy Director of the Central R&D Management Department of Shenzhen Mindray), William Sutton (Assistant Director in the Office of International Programs (OIP) at the United States Food and Drug Administration (FDA) China Office), and other authoritative speakers appeared to present speeches.

Medtec China this year continued to introduce the technology development forum on new medical dressings. Qin Yimin (Director of State Key Laboratory of Bioactive Seaweed Substances) was invited to introduce the properties and applications of silver-containing wound dressings, and Hu Fang (Board Chairman, Bestlife Regenerative Medicine) shared their insights on the selection and use of raw materials in the development and design of new high-end medical dressings.

Overall, there were 15 keynote forums covering 65 sessions of lectures; 53 invited speakers appeared to speak and share; and more than 1,500 industry representatives participated in the onsite events.

Medtec China 2020 will be held againfrom September 1416, 2020. High-quality brand suppliers from nearly 25 countries around the world will offer design, raw materials, precision parts, manufacturing equipment, processing technology, contract customization, testing and certification, policies and regulations, market consulting and other services required for product development, production and registration. It is expected to be attended by more than 30,000 visitors. A wealth of onsite events will offer premium opportunities for visiting and learning. For more information, please visit http://www.medtecchina.com.

Contact Us:Carina LiTel: +86-10-5730-6163E-mail: carina.li@ubm.comMedtec China Organization Committee

View original content to download multimedia:http://www.prnewswire.com/news-releases/medtec-china-2019-successfully-rounds-off-upgrading-to-two-pavilions-in-2020-to-power-innovative-development-of-chinas-medical-device-industry-300939535.html

SOURCE Medtec China

Read the original post:
Medtec China 2019 successfully rounds off; upgrading to two pavilions in 2020 to power innovative development of China's medical device industry -...

Heart failure remains the leading cause of mortality in the U.S. During a heart attack, blood stops flowing into the heart. Without oxygen, part of the heart muscle dies. The heart muscle does not regenerate, instead it replaces dead tissue with a scar made from cells called fibroblasts. If there is too much scarring, the heart progressively weakens. A large proportion of people who had a severe heart attack will develop heat failure and scarring in the heart.

One of the interests of my lab is to develop ways to heal heart muscle by studying cellular pathways involved in heart development and regeneration, said Dr. James F. Martin, professor and Vivian L. Smith Chair in Regenerative Medicine at Baylor College of Medicine and director of the Cardiomyocyte Renewal Lab at the Texas Heart Institute.

In previous studies, Martin and his colleagues discovered that inactivating the Hippo signaling pathway in adult murine hearts triggered cardiac muscle cell regeneration after heart attack. These findings raised hope for the development of promising heart failure therapies involving the Hippo pathway.

In the current study, Martin and his colleagues further investigated the Hippo pathway in the adult murine heart, this time focusing on its role in cardiac fibroblasts, non-muscle cells that are closely associated with cardiac muscle cells. The researchers conducted a number of basic studies, including single cell sequencing experiments that provided a high level of resolution to their analyses.

We inactivated the Hippo pathway in resting adult hearts that did not have any injury and observed that the fibroblasts became activated they proliferated and developed into myofibroblasts, a major cell type that appears in heart tissues after an injury, Martin said.

Mouse hearts with a deficient Hippo pathway in cardiac fibroblasts spontaneously developed cardiac fibrosis, even without injury, which resulted in severe heart dysfunction, said co-first author Dr. Yang Xiao, who was a postdoctoral fellow in the Martin lab during this project. This and other evidence indicated that the Hippo pathway is required to restrain cardiac fibrosis; Hippo is important for maintaining the fibroblasts in their resting state.

In addition, the researchers found that inactivating the Hippo pathway also triggered a molecular cascade resulting in an inflammatory response that was mediated by Yap, a molecule that regulates a number of molecular pathways.

We know that Hippo and Yap work together. Hippo acts like a brake for Yap, so when we took away Hippo, Yap remained active and regulated the expression of important signaling molecules that talk to macrophages and other immune cells luring them into the heart, Martin said.

The researchers believe they have identified important insights into heart function. Their findings inform about the genetic pathways that are important for maintaining the fibroblasts in their resting state.

Find the complete article in the journal Genes & Development.

Other contributors to this work include co-first author Matthew C. Hill, Lele Li, Vaibhav Deshmukh, Thomas J. Martin and Jun Wang. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, the Texas Heart Institute and the University of Texas Health Science Center at Houston.

This study was supported by grants from the National Institutes of Health (DE023177, HL127717, HL130804, HL118761; F31HL136065; K01DE026561); American Heart Association (14SDG19840000), Vivian L. Smith Foundation, State of Texas funding, Fondation LeDucq Transatlantic Networks of Excellence in Cardiovascular Research (14CVD01) Defining the genomic topology of atrial fibrillation. Further support was provided by Intellectual and Developmental Disabilities Research Center grant number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Mouse Phenotyping Core at Baylor College of Medicine (U54 HG006348).

By Ana Mara Rodrguez, Ph.D.

Original post:
What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News

Spontaneous recovery from disease is often painted as superstition but our body can heal itself

It may come as a surprise to some, especially those with conventional medical training, but the default state of the body is one of ceaselessregeneration. Without the flame-like process of continual cell turnover within the bodylife and death ceaselessly intertwinedthe miracle of the human body would not exist

In times of illness, however, regenerative processes are overcome by degenerative ones. This is where medicine may perform its most noble feat, nudging the body back into balance with foods, herbs, nutrients, and healing energies and intentions.

Today, however, drug-based medicine invariably uses chemicals that lackregenerative potential; to the contrary, they commonly interfere with bodily self-renewal in order to suppress the symptoms against which they are applied.

In other words, most medicines attack disease symptoms rather than support the bodys own ability to combat disease.

Over the course of the past few years of trolling MEDLINE (the National Institutes of Healths website produced by the National Library of Medicine), we have collected a series of remarkable studies on a topic considered all but heretical by the conventional medical systemspontaneous remission.

There is actually a broad range of natural compounds with proven nerve-regenerative effects. A 2010 study published in the journalRejuvenation Research, for instance, found a combination of blueberry, green tea and carnosine have neuritogenic (i.e. promoting neuronal regeneration) and stem-cell regenerative effects in an animal model ofneurodegenerative disease.Other researched neuritogenic substances include:

There is another class of nerve-healing substances, known asremyelinatingcompounds, which stimulate the repair of the protective sheath around the axon of the neurons known as myelin. Myelin is often damaged in neurological injury and/or dysfunction, especially autoimmune and vaccine-induceddemyelination disorders.

It should also be noted that evenmusicandfalling in lovehave been studied for possibly stimulating neurogenesis, regeneration and/or repair of neurons, indicating that regenerative medicine does not necessarily require the ingestion of anything; rather, a wide range oftherapeutic actionsmay be employed to improve health and well-being, as well.

[To view the first-hand biomedical citations on these neuritogenic substances, visit GreenMedinfosneuritogenicresearch page online.]

Glycyrrhizin, a compound found within licorice that is also a powerfulanti-SARS virus agent, has also been found to stimulate the regeneration of liver mass and function in the animal model of hepatectomy. Other liver regenerative substances include:

[To view the first-hand biomedical citations, visit GreenMedinfosliver regenerationresearch page on the topic online.]

The medical community has yet to harness the diabetes-reversing potential of natural compounds. Whereas expensive stem cell therapies, islet cell transplants, and an array of synthetic drugs in the developmental pipeline are the focus of billions of dollars of research, annually, our kitchen cupboards and backyards may already contain the long sought-after cure for type 1 diabetes. Nature has a way of providing the things our bodies need.

The following compounds have been demonstrated experimentally to regenerate the insulin-producing beta cells, which are destroyed in insulin-dependent diabetes, and once restored, may (at least in theory) restore the health of the patient to the point where they no longer require insulin replacement.

[To view the first-hand biomedical citations onbeta cell regeneration, visit GreenMedinfos research page on the topic online.]

Secretagogues are substances in the body that cause other substances to be secreted, like sulfonylureas, which triggers insulinrelease. Secretagogues, includingsynthetic secretagogues, can increase the endocrine glands ability to secrete more of a hormone. But even better are substances thattruly regeneratehormones which have degraded. They do this by emitting electrons into potentially carcinogenic transient hormone metabolites. One of these substances isvitamin C.

A powerful electron donor, this vitamin has the ability to contribute electrons to resurrect the form and function of estradiol (estrogen; E2), progesterone, and testosterone, for instance. In tandem withfoods that are able to support the function of glandslikethe ovaries, vitamin C may represent an excellent complement or alternative to hormone replacement therapy.

Not too long ago, it was believed that cardiac tissue was uniquely incapable of being regenerated. A new and rapidly growing body of experimental research now indicates that this is simply untrue. A class of heart-tissue regenerating compounds, known asneocardiogenicsubstances, are able to stimulate the formation of cardiac progenitor cells which can differentiate into healthy heart tissue. Neocardiogenicsubstances include the following:

Another remarkable example of cardiac cell regeneration is through what is known as the fetomaternal trafficking of stem cells through the placenta. The amazing process known as fetal microchimerism allows a fetus to contribute stem cells to the mother which are capable of regenerating her damaged heart cells, and possibly a wide range of other cell types.

Curcuminandresveratrolhave been shown to improve recovery from spinal cord injury. Over a dozen other natural compounds hold promise in this area, which can be viewed on GreenMedinfosspinal cord injurypage online. As far as degenerative joint disease, i.e. osteoarthritis, there are a broad range of potentially regenerative substances, with 50 listed on the sitesosteoarthritisresearch page.

Regenerative medicine poses a unique challenge to the current medical paradigm, which is based on costly drug trials, patents, and an economic infrastructure supported by drug-based interventions. It is a simple truth that symptom suppression is profitable. It guarantees both the perpetuation of the original underlying disease and the generation of an ever-expanding array of additional, treatment-induced symptoms known as side effects.

But cures, especially those that come from natural sources, dont have this built-in income potential. Worse perhaps, from a Big Pharma perspective, they can not be easily patented. In the current regulatory environment, that means that companies have no incentive to conduct the costly trials required to have these cures approved by the FDA and then used in clinical settings. Without patents, they cant be controlled and sold.

But suppressing symptoms with drugs that cause side effects requiring other drugs is a non-sustainable, infinite growth model. It is doomed to fail and eventually collapse.

The current approach also interferes with the bodys natural regenerative and immune capabilities. Cultivating diets, lifestyles and attitudes conducive to bodily regeneration can interrupt this pathological circuit. With true health, we can attain the bodily freedom that is a precondition for the liberation of the human spirit.

SayerJiis the founder ofGreenmedinfo.com, a reviewer at theInternational Journal of Human Nutrition and Functional Medicine, co-founder and CEO ofSystome Biomed, vice chairman of the board of theNational Health Federation, and steering committee member of theGlobal GMO Free Coalition.This article was originally published on GreenMedinfo.com

See the original post:
6 Bodily Tissues That Can Be Regenerated Through Nutrition - The Epoch Times

While aging equipment and bureaucracy continue to put a strain on the military's performance, training injuries are also taking a devastating toll.

Soldiers injured during training missed more than 4 million duty days in the first half of 2019 alone, medical researchers said during a panel at the Association of the US Army's conference in Washington, D.C.

"Injuries are the number-one medical threat to readiness," preventative medicine researcher Dr. Bruce Jones said Wednesday. "Musculoskeletal injuries, due mostly to training and vigorous operational activities, are the biggest portion of that problem."

More than three out of four of these kinds of injuries are from overuse. Running accounted for 43% of training injuries, according to Jones, making it the leading cause. Work-related tasks, equipment maintenance, and similar activities were also significant contributors.

The US Army

Research also showed that the slower the runner, the more they risked injury. And while the Army has strict body mass index requirements for its soldiers, Jones' research found those who had middle to high BMIs had less chance of injury compared with those with lower BMIs.

"So it appears being somewhat overweight, but physically fit, is protective against musculoskeletal issues," Jones said.

High rates of training injury given the requirements put on the modern soldier might not be surprising, but the Army has established a network of Army Wellness Center locations in an effort to promote a healthier force. The centers test a soldier's body fat composition, caloric needs, and aerobic capacity in order to help them meet their fitness goals.

"Instead of going [with] the traditional health education, health promotion, what we wanted to do was something a little bit more evidence-based," said Todd Hoover, the Army Wellness Center operations division chief. "So instead of just like lecturing people, holding classes, and stuff like that, what we wanted to do was assess where they're at."

The Army could see more soldiers injured in training as it begins to implement its new fitness test, which aims to mirror the physical requirements expected in the field. The new dead lift, for example, could increase back injuries for soldiers unfamiliar with proper weightlifting techniques.

Jones told the Washington Examiner he suspects there could be more injuries associated with the new test, but it's too soon to tell.

"The bottom line is we will have to wait and see," he said.

See the rest here:
The biggest threat to military readiness has nothing to do with combat - Business Insider

(All Peer News articles are submitted by readers of Citizen Truth and do not reflect the views of CT. Peer News is a mixture of opinion, commentary and news. Articles are reviewed and must meet basic guidelines but CT does not guarantee the accuracy of statements made or arguments presented. We are proud to share your stories, share yours here.)Changing from reactive based healthcare to proactive based healthcare could help Americans save millions.

Humana released a study on Monday, October 7 revealing that $265 billion is being wasted on healthcare in the U.S. annually. With medical costs already at staggering highs, many Americans cant afford to waste money on unneeded healthcare. After all, as CNBC reports, rising health-care costs are a reality and cause stress for many peopleIf we are to successfully confront the issues of cost and efficiency in care, we first need to fully understand the systemic problem of wasteful spending.

The last thing anyone wants to worry about during a medical emergency or when facing a chronic condition is the cost of healthcare. Unfortunately, for many Americans, worrying about healthcare costs is a reality. After all, the U.S. spends more on healthcare than any other country. In order to waste less money, the healthcare system must evolve to deliver more cost-efficient care to each and every patient.

The ultimate goal of the study conducted by Humana and the University of Pittsburgh School of Medicine was to estimate the levels of monetary waste on healthcare in the U.S. They focused on the top six aspects of healthcare that are attributed to wasting money, including:

The study found that the administrative complexity is the greatest source of monetary waste. Administrative complexity involves physician credentials, information systems, processing of medical claims, and administrative operating. Patients expect these responsibilities to be carried out seamlessly, however, clinicians and health plans typically work separately which can contribute to waste.

Each of these domains of healthcare will require different kinds of action to eliminate waste while improving patients experiences.

Prior to this newly released study, various initiatives have been implemented to help mitigate healthcare spending. Some of these initiatives include payment reform (bundled payments, value-based arrangements/reimbursements) and delivery reform (enhanced care coordination, Partnership for Patients initiative). However, these initiatives have only made a minor dent in healthcare spending waste and substantial waste still remains.

Sadly, the authors of the study found no reputable studies that have effectively found ways to reduce administrative complexity. Very few value-based payment options have been able to produce sufficient savings.

Don Berwick, a renowned physician and author of an editorial examining the Humana study, suggests that moving to a single-payer system, simplifying administrative costs, and lowering branded drug prices could help reduce waste.

Additionally, the Affordable Care Act implemented an effective preventative care plan that providers can follow to lower costs and prevent wasted money by treating diseases such as mental illness, diabetes, multiple sclerosis, and many other chronic diseases.

Too often, people wait until symptoms become severe to seek medical care. This can contribute to higher healthcare costs and chronic conditions. This is known as the reactive care model. Focusing more on proactive and preventative care, however, can help drive down long term healthcare costs. Proactive healthcare involves targeted communication and improved engagement allowing patients to take control of their own health outcomes. In addition, proactive healthcare focuses on more collaboration among patients and physicians in small-scale practices to help lower administrative costs, therefore, preventing administrative complexity waste.

Reactive healthcare is responsible for more than 75% of healthcare spending. Proactive and preventative healthcare, on the other hand, focuses on preventing chronic disease and improving healthcare outcomes. As a result, conditions can be tackled at the root causes and treated before they become a dangerous problem that requires costly medical care.

Innovative types of healthcare that are focusing on proactive and preventative health include workplace wellness initiatives, age management programs, and concierge medicine. Advocates for changing healthcare using preventative and proactive medicine suggest that proactive medicine treats diseases before they become a bigger problem saving patients time and money in the long run.

Aside from preventing disease, proactive healthcare is also proven to increase retention rates and extend patients lifetime value. Retention is vital to keeping healthcare costs low, as it costs 5 to 25 times more to treat new patients than it does to retain old ones.

While preventative medicine may not be the end-all-be-all solution to wasted healthcare costs, it can certainly play a role in preventing disease in order to keep costs down. It is evident that further research and initiatives need to be done to improve the efficiency of administrative complexity and healthcare spending. Its safe to say that healthcare reform is critical to lowering costs and expanding healthcare access to all Americans in need without the excessive worry of wasted money.

View post:
New Humana Study Suggests $1 out of $4 Spent on Healthcare Is Wasted Each Year - Citizen Truth

U.S.-based economists Abhijit Banerjee, Esther Duflo and Michael Kremer won the 2019 Nobel Economics Prize on Monday for work fighting poverty that has helped millions of children by favoring practical steps over theory.

French-American Duflo becomes only the second woman to win the economics prize in its 50-year history, as well as the youngest at 46. She shared the award equally with Indian-born American Banerjee and Kremer, also of the United States.

The Royal Swedish Academy of Sciences said their work had shown how poverty could be addressed by breaking it down into smaller and more precise questions in areas such as education and healthcare, and then testing solutions in the field.

It said the results of their studies and field experiments had ranged from helping millions of Indian schoolchildren with remedial tutoring to encouraging governments around the world to increase funding for preventative medicine.

"It starts from the idea that the poor are often reduced to caricatures and even the people that try to help them do not actually understand what are the deep roots of (their) problems," Duflo told reporters in Stockholm by telephone.

"What we try to do in our approach is to say, 'Look, let's try to unpack the problems one-by-one and address them as rigorously and scientifically as possible'," she added.

The team pioneered "randomized controlled trials," or RCTs, in economics. Long used in fields such as medicine, an RCT could for example take two groups of people and study what difference a treatment makes on one group while the other group is only given a placebo.

Applied to development economics, such field experiments found for example that providing more textbooks and free school meals had only small effects, while targeting help for weak students made a big difference to overall educational levels.

"It's a prize not just for us but for the whole movement," Banerjee later told a joint news conference at the Massachusetts Institute of Technology (MIT), where they both work. Kremer is a researcher at Harvard University.

Citing Banerjee's methods as having transformed classroom teaching in state schools in New Delhi, the Indian capital's chief minister Arvind Kejriwal said on Twitter that it was a "big day for every Indian."

Story continues

Continued here:
Nobel Econ winners 'excited' about their work - Yahoo News

The Smart MedTech Forum atSemicon Europa will focus on innovation and the future of medtechat Messe Mnchen from 12-15 November.

The SMART MedTech Forum fosterscollaboration across the semiconductor and medtech value chains, and gathers industry experts for insights into the latest developments and trends in medtech innovations driven by semiconductors.

The Forum will be located at theInspiration Hub, an pavilion where attendees can connect with companies behind medtech innovations, experience leading products, and discover startups.

It features the following sessions focused on the critical role of semiconductors and medtech in enabling technology innovation and solutions to the worlds most pressing healthcare challenges.

Global healthcare solutions

Janssen Pharmaceutical Companies of Johnson & Johnson will hold a presentation on global healthcare challenges and opportunities, followed by MedTech Europe, which will discuss trends in healthcare, the medtech industry and digital. imec and GE Research will focus on bridging the gap between semiconductors and medical technologies to solve global healthcare challenges.

Digitisation of preventive healthcare

The focus of more Smart medtech device companies on preventive medicine sets the stage for a presentation by OnePlanet Connected Health Solutions on opportunities in digital health for tracking mental stress using wearable data and machine learning. Maxim Integrated will explore the potential of sleep monitoring to prevent health problems and reduce healthcare costs, and how wearables can help prevent high blood pressure. ams AG will examine how sensors can enable consumer health applications for preventative healthcare.

Revolutionising healthcare with personalised medicine

Personalised medicine is on the rise in its aim to increase the efficiency and quality of care through customised patient management. Yole Developpement and Fraunhofer EMFT will introduce innovative solutions in precision medicine and drug delivery for personalised healthcare, while X-FAB will discuss how MEMS manufacturing is enabling breakthroughs in personalised medicine.

The digital patient: The future of artificial organs and human avatars

Digital patients promise to prevent and cure disease and transform healthcare through personalised treatment. Key figures from EPFL Lausanne, Philips, Robert Bosch, and Bart's Heart Centre will discuss quantum leaps in personalised treatment including the use of artificial organs, Organ-on-Chip, and human avatars as the next paradigm in healthcare.

Pioneering research in medical technologies

With fundamental research key to healthcare innovation, research and innovation centres imec and the KU Leuven will explore how CMOS-compatible technologies and systems can be applied to life sciences to enable platforms for personalised medicine.

Other SMART MedTech Forum highlights

The Medtech Startup Session will host startups including Sensome and its remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices. Onera Health and ChronoLife will introduce their diagnostic solutions, while PKvitality will present its health-monitoring smartwatches. ICAlps will present its products and services for the design and supply of ASIC/SOC integrated circuits for medtech applications.

Also, figures from ChronoLife, the European Commission and Siemens Healthineers will gather for the panel Key Drivers Transforming Healthcare: AI, Big Data and Cybersecurity, three areas central to medtech advances.

The rest is here:
Semicon Europa to host Smart MedTech Forum in Munich - Med-Tech Innovation

The Vandal Health Clinic formerly known as the Student Health Clinic will move back to its Moscow campus location this fall.

The clinic was moved off campus last year to the downtown location of Moscow Family Medicine. It was moved again and is now located next to the QuickCare clinic behind WalMart.

We dont have a definitive date of being open, but itll be soon, Dean of Students Blaine Eckles said. Likely before Thanksgiving, if not sooner than that.

The on-campus clinic, located in the same building as the Student Health Insurance Office and Vandal Health Education, is in the final stages of being remodeled, Eckles said.

ICYMI: CTC fills psychiatry void

The clinic will house six exam rooms, a procedure room, office space for physicians and an x-ray room. It is unclear at this time if the clinic will have the capacity to do other types of lab work on site, but those resources will remain available through other healthcare facilities in Moscow.

There is room within the current space to expand.

The move (back to campus) was ultimately my decision, Eckles said. I dothat in consultation with campus leadership, the president. This conversation started last spring as an opportunity for us to engage. President Staben and Provost Wiencek were in support of that, President Green is in support of it as well.

The clinic was moved to the Gritman Medical Center location behind WalMart during the remodeling process because that location had the capacity to meet student needs better than the downtown Moscow Family Medicine location, Eckles said.

Moscow Family Medicine integrated with Gritman Medical Center last year, Eckles said, which allowed this move to happen.

Eckles said the team behind the move wanted to open the clinic sooner, but the remodel took time. It was originally predicted to open in January, but Eckles said the clinic is likely to open much sooner.

The physician who will be based out of the clinic, Dr. Jacob Christensen, completed a Primary Care Sports Medicine Fellowship at the University of New Mexico last summer and began seeing patients at the current clinic location recently.

Christensen will provide general healthcare in addition to mental, preventative and womens health services. He will also work with University of Idaho athletic teams as an athletic physician.

Eckles and Christiansen said there should not be any changes in services when the location of the clinic changes.

ICYMI: UI employees to expect higher rates for healthcare coverage

Some types of lab work may be unavailable on site, Christianson said, but finding alternatives and other local resources should not be a problem.

The Vandal Health Clinic will be open five days per week including over academic breaks and will be open to students, staff, faculty and other members of the campus community. Eckles said this will provide another line of healthcare service for students and ease access to services throughout Moscow, cutting down line sizes and wait times.

Eckles said he will send out a campus-wide email once a final opening date has been set for the clinic. The team plans to host a ribbon-cutting ceremony when the clinic opens.

Alexis Van Horn can be reached at arg-news@uidaho.edu or on Twitter @AlexisRVanHorn

Read more from the original source:
Health clinic to return to University of Idaho campus - Argonaut